Abstracts tagged "Gout and uric acid"

Abstract Number: 2109 • 2015 ACR/ARHP Annual Meeting
Racial Disparities in the Risk of Hospitalized Severe Allopurinol Hypersensitivity Syndrome – a US Nationwide Study (2009-2011)
Na Lu¹, Sharan K. Rai², Jeewoong Choi³ and Hyon K. Choi¹, ¹Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Experimental Medicine, University of British Columbia, Vancouver, BC, Canada, ³Massachusetts College of Pharmacy and Health Sciences, Boston, MA
Background/Purpose: Allopurinol is the leading choice of urate-lowering therapy for gout (>95% of treated cases); however, it is associated with the rare but potentially fatal…
Abstract Number: 2111 • 2015 ACR/ARHP Annual Meeting
A Study to Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients
Alexandra Steinberg¹, Harinder Chera¹, Yun-Jung Choi¹, Robert Martin¹, Charles McWherter¹, Yunbin Zhang², Pol Boudes¹ and on behalf of the Arhalofenate Anti-Flare Therapy Study Group, ¹Cymabay Therapeutics, Newark, CA, ²INC Research, Raleigh, NC
Background/Purpose: Arhalofenate is a novel Urate-Lowering Anti-Flare Therapy (ULAFT) to treat gout. It lowers serum uric acid (sUA) by blocking URAT1, a tubular UA transporter, and…
Abstract Number: 2355 • 2015 ACR/ARHP Annual Meeting
Effects of the Dietary Approaches to Stop Hypertension (DASH) Diet on Serum Uric Acid Levels: A Randomized Controlled Trial
Na Lu¹, Yuqing Zhang², Sharan K. Rai³, Gary C. Curhan⁴ and Hyon K. Choi⁵, ¹Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²BUSM, Boston, MA, ³Experimental Medicine, University of British Columbia, Vancouver, BC, Canada, ⁴Renal Division, Brigham and Women's Hospital, Boston, MA, ⁵Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: There is a remarkable, increasing disease burden of gout and its associated cardiovascular-metabolic comorbidities (e.g., hypertension in 74% of cases in the US), underscoring…
Abstract Number: 91 • 2015 ACR/ARHP Annual Meeting
Coevolution of a Uric Acid Transporter and Uricase: Implications for Gout
Philip K. Tan¹, Eric A. Gaucher² and Jeffrey N. Miner³, ¹Ardea Biosciences, San Diego, CA, ²Georgia Institute of Technology, Atlanta, GA, ³Discovery Biology, Ardea Biosciences, San Diego, CA
Background/Purpose: Gout is caused by chronic hyperuricemia, leading to uric acid deposition. Humans and apes have relatively high serum uric acid (sUA) levels due to…
Abstract Number: 121 • 2015 ACR/ARHP Annual Meeting
Serum Uric Acid Levels and Gout Flares in a US Managed Care Setting
Aki Shiozawa¹, Erin Buysman², Stephanie Korrer² and Hyon Choi³, ¹Global Outcomes and Epidemiology Research, Takeda Pharmaceuticals International, Inc, Deerfield, IL, ²Health Economics and Outcomes Research, Optum, Eden Prairie, MN, ³Massachussetts General Hospital/Harvard Medical School, Boston, MA
Background/Purpose: Gout is a common chronic inflammatory condition due to hyperuricemia. Gout patients typically have the clinical manifestation of acute painful flare attacks. While the…
Abstract Number: 218 • 2015 ACR/ARHP Annual Meeting
Diet-Wide Association Study of Serum Urate Levels in 13,782 Individuals of European Ancestry
Tony R. Merriman¹, Nicola Dalbeth², Ruth Topless³ and Tanya Flynn³, ¹Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand, ²Department of Medicine, University of Auckland, Auckland, New Zealand, ³University of Otago, Dunedin, New Zealand
Background/Purpose: Gout is a consequence of an innate immune reaction to monosodium urate crystals deposited in joints. Acute gout attacks are commonly triggered by dietary…
Abstract Number: 219 • 2015 ACR/ARHP Annual Meeting
Targeted Deep Resequencing Identifies MRP4/ABCC4 as a Gout Risk Locus in the New Zealand Mä�ori and Pacific Island Populations
Tony R. Merriman¹, James Boocock², Callum Tanner², Murray Cadzow², Amanda Phipps-Green², Lisa K. Stamp³, Nicola Dalbeth⁴, Jennie Harre Hindmarsh⁵, David B. Mount⁶, Hyon Choi⁷ and Eli A. Stahl⁸, ¹Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand, ²University of Otago, Dunedin, New Zealand, ³Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ⁴Department of Medicine, University of Auckland, Auckland, New Zealand, ⁵Ngati Porou Hauora Charitable Trust, Te Puia Springs, New Zealand, ⁶Renal Division, Brigham and Women's Hospital, Boston, MA, ⁷Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁸Divisions of Rheumatology and Genetics, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Genetic variants in uric acid transporters that control serum urate levels in Europeans have been identified by genome-wide association studies. However there is no…
Abstract Number: 228 • 2015 ACR/ARHP Annual Meeting
Gout and Risk of Non-Vertebral Osteoporotic Fracture
Seoyoung C. Kim¹, Julie M. Paik², Jun Liu³, Gary C. Curhan² and Daniel H. Solomon⁴, ¹Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Renal Division, Brigham and Women's Hospital, Boston, MA, ³Division of Pharmaoepidemiology, Brigham and Women's Hospital, Boston, MA, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Prior studies suggest an association between osteoporosis, systemic inflammation and pro-inflammatory cytokines such as IL-1 and IL-6. Gout is a common inflammatory arthritis characterized…
Abstract Number: 229 • 2015 ACR/ARHP Annual Meeting
Uric Acid and Incident Dementia over 10 Years
Pascal Richette¹, Aicha Soumare², Stéphanie Debette², Thomas Bardin^3,4 and Christophe Tzourio², ¹Université Paris Diderot, UFR médicale, Paris, France; APHP Hôpital Lariboisière, Fédération de Rhumatologie and Inserm U1132, Hôpital Lariboisière, Paris, France, ²INSERM Research Center for Epidemiology and Biostatistics (U897) Team Neuroepidemiology, Bordeaux, France, ³Service de Rhumatologie, Hôpital Lariboisière, Paris, France, ⁴Rhumatology Departement, Hôpital Lariboisière, Paris, France
Background/Purpose: In patients with gout, maintaining the serum uric acid (SUA) levels too low with ULT is a matter of concern because UA is thought…
Abstract Number: 242 • 2015 ACR/ARHP Annual Meeting
Higher Serum Uric Acid Levels Are Associated with an Increased Risk of Flares: A Systematic Review
Aki Shiozawa¹, Shelagh M Szabo², Antoinette Cheung², Anna Bolzani² and Hyon K. Choi³, ¹Global Outcomes and Epidemiology Research, Takeda Pharmaceuticals International, Inc, Deerfield, IL, ²Redwood Outcomes, Vancouver, BC, Canada, ³Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Acutely painful flares represent the typical clinical burden of gout. Effective therapy can reduce serum uric acid (sUA) levels; however, epidemiologic evidence for the…
Abstract Number: 245 • 2015 ACR/ARHP Annual Meeting
Seasonal Variation in Acute Gouty Arthritis: Data from Nationwide Inpatient Sample
Paras Karmacharya¹, Ranjan Pathak², Madan Aryal², Smith Giri³ and Anthony Donato⁴, ¹Internal Medicine, Reading Health System, WEST READING, PA, ²Internal medicine, Reading Health System, West Reading, PA, ³Internal medicine, University of Tennessee Health Science Center, Memphis, TN, ⁴Internal, Reading Health System, Salt Lake, UT
Background/Purpose: Studies describing seasonal variations in acute gouty arthritis note a seasonal trend, but disagree on timing, with most showing a peak in spring months…
Abstract Number: 935 • 2015 ACR/ARHP Annual Meeting
Microrna-146a Provides Feedback Regulation of Monosodium Urate-Induced Gouty Arthritis in Mice By Targeting Tumor Necrosis Factor Receptor Associated Factor 6 and Interleukin-1 Receptor-Associated Kinase 1
Quan-Bo Zhang^1,2, Jing-Guo Zhou³, Cong-Cong Yin¹, Yu-Feng Qing⁴, Chang-Gui Li⁵, Li Zhou¹ and Qing-Sheng Mi⁶, ¹Immunology Program, Department of Dermatology, Henry Ford Health System, Detroit, MI, ²Geriatrics, Affliated hospital of North Sichuan Medical College, Nanchong, China, ³Department of Rheumatology and Immunology, Affliated hospital of North Sichuan Medical College, Nanchong, China, ⁴Affiliated Hospital of North Sichuan Medical College, Sichuan 637000, China, Nanchong, China, ⁵Affiliated Hospital of Qingdao University, Qingdao, China, ⁶Immunology, Dermatology, Henry Ford Health System, Detroit, MI
Background/Purpose: MicroRNAs (miRNAs) have been shown to serve as important regulators for inflammatory and immune responses and are implicated in several immune disorders including gouty…
Abstract Number: 1221 • 2014 ACR/ARHP Annual Meeting
Serum Uric Acid As an Independent Risk Factor on Progression of Chronic Kidney Disease in Gout Patients with Uric Acid Lowering Agent
Young Hyup Lim¹, Eun-Jung Park¹, Seulkee Lee², Hemin Jeong³, Hyungjin Kim⁴, Jinseok Kim¹, Jaejoon Lee⁵, Hoon-Suk Cha³ and Eun-Mi Koh⁶, ¹Internal Medicine, Department of Medicine, Jeju National University Hospital, Jeju University School of Medicine, Republic of Korea, Jeju, South Korea, ²Internal Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, Seoul, South Korea, ³Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁴Internal Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, Seul, South Korea, ⁵Division of Rheumatology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁶Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Background/Purpose Hyperuricemia is particularly common in patients with chronic kidney disease (CKD). Its role, however, as a risk factor for renal outcomes of CKD is…
Abstract Number: 1217 • 2014 ACR/ARHP Annual Meeting
The Random Urine Uric Acid to Creatinine Ratio As a Predictor of 24-Hour Urine Uric Acid Excretion in Gout Patients
Sang Tae Choi¹, Jung-Soo Song² and Eun-Hye Park², ¹Internal Medicine, Chung-Ang University College of Medicine, Seoul, South Korea, ²Chung-Ang University College of Medicine, Seoul, South Korea
Background/Purpose: Gout is an inflammatory disease resulted from an increased body pool of uric acid. The measurement of 24-hour uric acid excretion is important to…
Abstract Number: 830 • 2014 ACR/ARHP Annual Meeting
Profound Hypouricemia Induced in Human Subjects By Novel Bifunctional Inhibitors of Xanthine Oxidase and URAT1
Raymond P. Warrell Jr.¹, Anna Klukovits², Keith Barnes³, Chitkala Satyanarayana⁴, Chris Cheeseman⁵ and John Piwinski¹, ¹Relburn-Metabolomics, Inc., Westfield, NJ, ²SOLVO Biotechnology, Budapest, Hungary, ³AMRI, Albany, NY, ⁴AMRI, Singapore, Singapore, ⁵University of Alberta, Alberta, AB, Canada
Background/Purpose: A prototype anticancer drug (RLBN1001) induced marked hypouricemia in studies of > 350 human subjects. Preliminary exploration suggested dual effects on uric acid (UA)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].